United Therapeutics (UTHR) Cash from Investing Activities Growth (5y) (2014 - 2026)
Powered by 
Analysis
United Therapeutics (UTHR) Cash from Investing Activities Growth (5y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.52 Bn | 15.13 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 30.53% |
| Mar 31, 2026 | 160.54% |
| Dec 31, 2025 | -28.96% |
| Sep 30, 2025 | 20.29% |
| Jun 30, 2025 | 4.39% |
| Mar 31, 2025 | -42.94% |
| Dec 31, 2024 | -31.02% |
| Sep 30, 2024 | 17.39% |
| Jun 30, 2024 | -13.43% |
| Mar 31, 2024 | 69.99% |
| Dec 31, 2023 | 20.90% |
| Sep 30, 2023 | 1.02% |
| Jun 30, 2023 | 8.78% |
| Mar 31, 2023 | -30.37% |
| Dec 31, 2022 | 7.42% |
| Sep 30, 2022 | 14.03% |
| Jun 30, 2022 | 2.46% |
| Mar 31, 2022 | -16.75% |
| Dec 31, 2021 | -90.42% |
| Sep 30, 2021 | -68.88% |